Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

Phase 3 Completed 136 enrolled ABX advanced biochemical compounds GmbH

NaSingle-groupOpen-labelDiagnostic

Summary

This study evaluates the diagnostic performance and safety of \[18F\]PSMA-1007 PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.

Timeline

Start: 2021-08-27
Primary completion: 2023-06-23
Completion: 2025-05-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	18F-PSMA-1007	Diagnostic / imaging agent	—	Intravenous

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

Summary

Timeline

Drugs

Indications